Zhengye Biotechnology Holding Limited Ordinary Shares Cash Flow-to-Debt Ratio
Zhengye Biotechnology Holding Limited Ordinary Shares cash flow-to-debt ratio. Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) has a Cash Flow-to-Debt Ratio of 0.29x as of December 2025, meaning its operating cash flow of $41.05 Million could theoretically repay 0% of its total liabilities ($140.71 Million) in one year. Check Zhengye Biotechnology Holding Limited Or earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Zhengye Biotechnology Holding Limited Ordinary Shares (2021–2025)
Cash flow-to-debt ratio of Zhengye Biotechnology Holding Limited Ordinary Shares from 2021 to 2025. Historical debt coverage capacity for Zhengye Biotechnology Holding Limited Ordinary Shares across 5 annual periods. Check ZYBT cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Zhengye Biotechnology Holding Limited Ordinary Shares Cash Flow-to-Debt Ratio by Year (2021–2025)
Zhengye Biotechnology Holding Limited Ordinary Shares cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Zhengye Biotechnology Holding Limited Ordinary Shares. For the full cash flow conversion analysis, see ZYBT operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | $41.05 Million | $140.71 Million | ▲ +0.0% |
| 2024 | 0.29x | $41.05 Million | $140.71 Million | ▼ -2.8% |
| 2023 | 0.30x | $48.18 Million | $160.62 Million | ▲ +181.7% |
| 2022 | 0.11x | $17.34 Million | $162.81 Million | ▼ -57.7% |
| 2021 | 0.25x | $31.81 Million | $126.44 Million | — |